Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
BJOG. 2022 May;129(6):917-925. doi: 10.1111/1471-0528.17028. Epub 2021 Dec 9.
To investigate whether users of hormonal contraceptives (HCs) are at increased risk of depression compared with non-users.
Register-based cohort study.
Sweden.
Women aged 15-25 years between 2010 and 2017 with no prior antidepressant treatment, psychiatric diagnose or contraindication for HCs (n = 739 585).
Women with a prescription of HC were identified via the Swedish Prescribed Drug Register (SPDR). Relative risks (RRs) for first depression diagnosis in current HC-users compared with non-users were modelled by Poisson regression. Adjustments included age, medical indication for HC-use and parental history of mental disorders, among others.
Depression, captured by a redeemed prescription of antidepressant treatment, or a first depression diagnosis in the SPDR and the National Patient Register.
Compared with non-users, women on combined oral contraceptives (COCs) and oral progestogen-only products had lower or no increased risk of depression, relative risk (RR) 0.89 (95% CI 0.87-0.91) and 1.03 (95% CI 0.99-1.06) after adjustments, respectively. Age-stratified analyses demonstrated that COC use in adolescents conferred no increase in risk (RR 0.96, 95% CI 0.93-0.98), whereas use of progestogen-only pills (RR 1.13, 95% CI 1.07-1.19), contraceptive patch/vaginal ring (RR 1.43, 95% CI 1.30-1.58), implant (RR 1.38, 95% CI 1.30-1.45) or a levonorgestrel intrauterine device (RR 1.59, 95% CI 1.46-1.73) were associated with increased risks.
This study did not find any association between use of COCs, which is the dominating HC in first time users, and depression. Non-oral products were associated with increased risks. Residual confounding must be addressed in the interpretation of the results.
There is no association between combined hormonal contraceptives and depression.
研究与非使用者相比,使用激素避孕药(HCs)的患者是否有更高的抑郁风险。
基于注册的队列研究。
瑞典。
2010 年至 2017 年间年龄在 15-25 岁之间、无既往抗抑郁治疗、精神科诊断或 HCs 禁忌证的女性(n=739585)。
通过瑞典处方药物登记册(SPDR)确定使用 HCs 的女性。通过泊松回归模型,比较当前 HCs 使用者和非使用者首次抑郁诊断的相对风险(RR)。调整因素包括年龄、HC 使用的医学指征以及父母的精神障碍史等。
通过抗抑郁药物治疗或 SPDR 和国家患者登记处的首次抑郁诊断,来确定抑郁情况。
与非使用者相比,服用复方口服避孕药(COC)和口服单纯孕激素产品的女性发生抑郁的风险较低或无增加,调整后 RR 分别为 0.89(95%CI 0.87-0.91)和 1.03(95%CI 0.99-1.06)。年龄分层分析表明,青春期女性服用 COC 不会增加风险(RR 0.96,95%CI 0.93-0.98),而服用单纯孕激素避孕丸(RR 1.13,95%CI 1.07-1.19)、避孕贴片/阴道环(RR 1.43,95%CI 1.30-1.58)、植入物(RR 1.38,95%CI 1.30-1.45)或左炔诺孕酮宫内节育器(RR 1.59,95%CI 1.46-1.73)与风险增加相关。
本研究未发现 COC 使用与抑郁之间存在任何关联,而 COC 是初次使用者中最主要的 HCs。非口服产品与风险增加相关。在解释结果时必须考虑到残留混杂因素。
使用复方激素避孕药与抑郁无关。